Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cycles ...

TERN-701 more than doubled the response rate of Novartis’ rival approved therapy in an early-stage trial, sending the biotech ...

In the phase 2 FASCINATION trial, researchers sought to improve the rate of major molecular response 4 in patients newly diagnosed with CML.

The primary end point of the study, major molecular response at 12 months, was achieved by 69% of patients. Approximately a ...

Discover why Terns Pharmaceuticals, Inc. stock is up 770% YTD with strong CML drug data and major upcoming milestones. Click ...

Cases of CML-BP that met following selection criteria were included in this study: 1, CML-BP diagnosed from 2001 to 2016; 2, presence of t(9;22)(q34;q11.2) or variant translocations detected by ...

While early, study results presented at ASH show Tern’s drug could surpass Novartis’ Scemblix and “raise the bar in efficacy” ...

Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy One hundred sixteen patients in durable CGCR, and ...

Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorablesafety ...

A total of 610 (30%) patients had ACAs in addition to t(9;22)(q34;q11.2)/BCR-ABL. Of note, cases with chromosomal changes in Ph-negative cells were not considered as ACAs. Of 610 cases with ACAs, 183 ...

With today’s medicines, most people with chronic myeloid leukemia (CML) have a normal lifespan and a good quality of life. The key is to get care from CML experts — like the physicians at Fred ...